MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that have a pivotal role in the post-transcriptional regulation of gene expression by sequence-specifically targeting multiple mRNAs. Although miR-33a was recently reported to play an important role in lipid homeostasis, atherosclerosis, and hepatic fibrosis, the functions of miR-33a in tumor progression and metastasis are largely unknown. Here, we found that downregulated miR- 33a in breast cancer tissues correlates with lymph node metastasis. MiR-33a expression is significantly lower in the highly metastatic breast cancer cell lines than the noncancerous breast epithelial cells and non-metastatic breast cancer cells. Moreover, the overexpression of miR-33a in metastatic breast cancer cells remarkably decreases cell proliferation and invasion in vitro and significantly inhibits tumor growth and lung metastasis in vivo, whereas its knockdown in non-metastatic breast cancer cells significantly enhances cell proliferation and invasion in vitro and promotes tumor growth and lung metastasis in vivo. Combining bioinformatics prediction and biochemical analyses, we showed that ADAM9 and ROS1 are direct downstream targets of miR-33a. These findings identified miR-33a as a negative regulator of breast cancer cell proliferation and metastasis.

Keywords

miR-33a / breast cancer / proliferation / metastasis

References

[1] Aleckovic M, Kang Y (2015) Regulation of cancer metastasis by cellfree miRNAs. Biochim Biophys Acta 1855:24–42

[2] Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870

[3] Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO et al (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:R214

[4] Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559–1564

[5] Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z, Yang CJ, Yuan L, Ouyang G (2011) Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 30:4707–4720

[6] Hong W, Dong E (2014) The past, present and future of breast cancer research in China. Cancer Lett 351:1–5

[7] Ibrahim AF, Weirauch U, Thomas M, Grunweller A, Hartmann RK, Aigner A (2011) MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 71:5214–5224

[8] Li ZJ, Ou-Yang PH, Han XP (2014) Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal 26:141–148

[9] Liu AY, Cai Y, Mao Y, Lin Y, Zheng H, Wu T, Huang Y, Fang X, Lin S, Feng Q et al (2014) Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 35:537–545

[10] Lu S, Azada MC, Ou SH (2015) Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lung Cancer 87:207–209

[11] Marquart TJ, Allen RM, Ory DS, Baldan A (2010) miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 107:12228–12232

[12] Micocci KC, Martin AC, Montenegro Cde F, Durante AC, Pouliot N, Cominetti MR, Selistre-de-Araujo HS (2013) ADAM9 silencing inhibits breast tumor cell invasion in vitro. Biochimie 95:1371–1378

[13] Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328:1566–1569

[14] O’Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O’Higgins N, Duffy MJ (2003) Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer (Journal international du cancer) 105:754–761

[15] Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C (2010) MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328:1570–1573

[16] Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X et al (2011) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:404–407

[17] Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D (2008) Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 90:369–379

[18] Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285:116–126

[19] Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971

[20] Thomas M, Lange-Grunweller K, Weirauch U, Gutsch D, Aigner A, Grunweller A, Hartmann RK (2012) The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 31:918–928

[21] Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, Croce CM (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA 109:3024–3029

[22] Wan L, Pantel K, Kang Y (2013) Tumor metastasis: moving new biological insights into the clinic. Nat Med 19:1450–1464

[23] Wang Z, Ouyang G (2012) Periostin: a bridge between cancer stem cells and their metastatic niche. Cell Stem Cell 10:111–112

[24] Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon RE, Friedman AH, Keir ST et al (2014) miR-33a promotes gliomainitiating cell self-renewal via PKA and NOTCH pathways. J Clin Investig 124:4489–4502

[25] Zheng L, Baumann U, Reymond JL (2004) An efficient one-step sitedirected and site-saturation mutagenesis protocol. Nucleic Acids Res 32:e115

[26] Zhou Y, Huang Z, Wu S, Zang X, Liu M, Shi J (2014) miR-33a is upregulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res 33:12

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.